IL2 and lung carcinoma: This study shown that the mPFS of the IPCGOR combined with IL-2 regimen was 8.5 months, MOS was 12.5 months, and ORR was 58.3%, underscoring the significant implications of promoting IPCGOR combined with IL-2 treatment in progressive lung cancer, further confirming the effectiveness and safety of the IPCGOR combined with IL-2 regimen.